Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis

Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; José Ángel Hernández-Rivas; Keqin Qi; Sanjay Deshpande; Lori Parisi; Michael Wang

doi:10.3324/haematol.2018.205229

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis

Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, José Ángel Hernández-Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang

Lymphoma-Myeloma

Research output: Contribution to journal › Letter › peer-review

114 Scopus citations

Original language	English (US)
Pages (from-to)	e211-e214
Journal	Haematologica
Volume	104
Issue number	5
DOIs	https://doi.org/10.3324/haematol.2018.205229
State	Published - Apr 30 2019

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.3324/haematol.2018.205229

Cite this

@article{05bb60dd41b0485a927ce046785e9ba6,

title = "Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis",

author = "Simon Rule and Martin Dreyling and Andre Goy and Georg Hess and Rebecca Auer and Brad Kahl and Hern{\'a}ndez-Rivas, {Jos{\'e} {\'A}ngel} and Keqin Qi and Sanjay Deshpande and Lori Parisi and Michael Wang",

note = "Funding Information: 1Department of Haematology, Plymouth University Medical School, UK;2Department of Medicine III, Klinikum der Universit{\"a}t M{\"u}nchen, LMU, Germany;3Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA;4Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany;5Centre for Haemato-Oncology, Barts Cancer Institute, London, UK;6Department of Medicine, Washington University, St. Louis, MO, USA;17Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain;8Janssen Research & Development, Raritan, NJ, USA and 9Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Funding: this study was sponsored by Janssen Research & Development. Writing assistance was provided by Liqing Xiao and Natalie Dennis of PAREXEL and was funded by Janssen Global Services, LLC.",

year = "2019",

month = apr,

day = "30",

doi = "10.3324/haematol.2018.205229",

language = "English (US)",

volume = "104",

pages = "e211--e214",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "5",

}

TY - JOUR

T1 - Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

T2 - Extended 3.5-year follow up from a pooled analysis

AU - Rule, Simon

AU - Dreyling, Martin

AU - Goy, Andre

AU - Hess, Georg

AU - Auer, Rebecca

AU - Kahl, Brad

AU - Hernández-Rivas, José Ángel

AU - Qi, Keqin

AU - Deshpande, Sanjay

AU - Parisi, Lori

AU - Wang, Michael

N1 - Funding Information: 1Department of Haematology, Plymouth University Medical School, UK;2Department of Medicine III, Klinikum der Universität München, LMU, Germany;3Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA;4Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany;5Centre for Haemato-Oncology, Barts Cancer Institute, London, UK;6Department of Medicine, Washington University, St. Louis, MO, USA;17Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain;8Janssen Research & Development, Raritan, NJ, USA and 9Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Funding: this study was sponsored by Janssen Research & Development. Writing assistance was provided by Liqing Xiao and Natalie Dennis of PAREXEL and was funded by Janssen Global Services, LLC.

PY - 2019/4/30

Y1 - 2019/4/30

UR - http://www.scopus.com/inward/record.url?scp=85065467837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065467837&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.205229

DO - 10.3324/haematol.2018.205229

M3 - Letter

C2 - 30442728

AN - SCOPUS:85065467837

SN - 0390-6078

VL - 104

SP - e211-e214

JO - Haematologica

JF - Haematologica

IS - 5

ER -

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this